Education
About Us
Working with TipRanks
Follow Us
MiMedx Group (MDXG)
NASDAQ:MDXG
MDXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.47 - $10.14
Previous CloseN/A
Volume99.42K
Average Volume (3M)925.13K
Market Cap
$1.06B
Enterprise Value$811.92M
Total Cash (Recent Filing)$106.43M
Total Debt (Recent Filing)$18.66M
Price to Earnings (P/E)33.2
Beta0.78
Next Earnings
Oct 29, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding147,959,410
10 Day Avg. Volume1,003,542
30 Day Avg. Volume925,135
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue2.30
Enterprise Value/Gross Profit2.81
Enterprise Value/Ebitda14.78
Forecast
1Y Price Target
$11.00Price Target Upside57.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Product SalesMDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.
Strategic InitiativesManagement remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.
Bears Say
Reimbursement UncertaintyContinuing reimbursement uncertainty disrupted the business in the physician office setting.
MiMedx Group News
MDXG FAQ
What was MiMedx Group’s price range in the past 12 months?
MiMedx Group lowest stock price was $5.47 and its highest was $10.14 in the past 12 months.
What is MiMedx Group’s market cap?
MiMedx Group’s market cap is $1.06B.
When is MiMedx Group’s upcoming earnings report date?
MiMedx Group’s upcoming earnings report date is Oct 29, 2025 which is in 83 days.
How were MiMedx Group’s earnings last quarter?
MiMedx Group released its earnings results on Jul 30, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.054 by $0.006.
Is MiMedx Group overvalued?
According to Wall Street analysts MiMedx Group’s price is currently Undervalued.
Does MiMedx Group pay dividends?
MiMedx Group does not currently pay dividends.
What is MiMedx Group’s EPS estimate?
MiMedx Group’s EPS estimate is 0.06.
How many shares outstanding does MiMedx Group have?
MiMedx Group has 147,959,410 shares outstanding.
What happened to MiMedx Group’s price movement after its last earnings report?
MiMedx Group reported an EPS of $0.06 in its last earnings report, beating expectations of $0.054. Following the earnings report the stock price went up 10.276%.
Which hedge fund is a major shareholder of MiMedx Group?
Currently, no hedge funds are holding shares in MDXG
MiMedx Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (57.82% Upside)
$11.00 (57.82% Upside)
Blogger Sentiment
Bullish
MDXG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 335.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.68%
12-Months-Change
Fundamentals
Return on Equity
16.62%
Trailing 12-Months
Asset Growth
26.47%
Trailing 12-Months
Company Description
MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MDXG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance with record revenue and EBITDA figures, robust growth in key segments, and strategic advancements. However, concerns surrounding regulatory changes and trial enrollment challenges present potential headwinds. Despite these challenges, the overall sentiment remains positive due to the company's strong financial position and increased guidance.View all MDXG earnings summariesMDXG Stock 12 Month Forecast
Average Price Target
$11.00
▲(57.82% Upside)
Technical Analysis
Celldex
―
Iovance Biotherapeutics
―
Ardelyx
―
Ocular Therapeutix
―
Liquidia Technologies
―
Ownership Overview
2.18% Insiders
9.13% Mutual Funds
0.84% Other Institutional Investors
77.64% Public Companies and
Individual Investors